RESPONSE OF CANINE SOFT-TISSUE SARCOMAS TO RADIATION OR RADIATION PLUS HYPERTHERMIA - A RANDOMIZED PHASE-II STUDY

被引:48
|
作者
GILLETTE, SM
DEWHIRST, MW
GILLETTE, EL
THRALL, DE
PAGE, RL
POWERS, BE
WITHROW, SJ
ROSNER, G
WONG, C
SIM, DA
机构
[1] COLORADO STATE UNIV,DEPT RADIOL & RADIAT BIOL,FT COLLINS,CO 80523
[2] COLORADO STATE UNIV,DEPT CLIN SCI,FT COLLINS,CO 80523
[3] DUKE UNIV,MED CTR,DIV RADIAT ONCOL,DURHAM,NC 27710
[4] N CAROLINA STATE UNIV,COLL VET MED,RALEIGH,NC
[5] JOHN P ROBARTS RES INST,CLIN TRIALS RES GRP,LONDON N6A 5KB,ONTARIO,CANADA
关键词
HYPERTHERMIA; RADIATION; CANINE SARCOMAS;
D O I
10.3109/02656739209021786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sixty-four dogs with spontaneous soft tissue sarcomas without evidence of metastases were stratified by tumour volume and randomized to receive graded doses of radiotherapy (XRT) alone or radiotherapy plus hyperthermia (HT). An improvement in duration of local control was achieved with the addition of hyperthermia as compared with XRT alone (Wilcoxon, p = 0.040; log rank, p = 0.064). Overall frequency of late complications was not different for the two treatment arms when comparing across equivalent XRT dose groups. Frequency of distant metastases after therapy completion was not significantly different for the two treatment arms at 1 year (7.4% for XRT versus 20% for HT plus XRT) or 2 years (11.5% for XRT versus 25% tor HT plus XRT) post therapy. These results suggest that a therapeutic gain was achieved for this group of tumour-bearing animals. Uni- and multivariate analyses were performed to examine the potential for various factors to influence treatment outcome. Patient related variables included tumour stage. histologic subtype and grade and tumour site. Treatment related variables included total radiation dose and 15 descriptors of temperature distributions achieved during hyperthermia. When considering patient related factors, tumour histology, grade and location were important predictors of time to minimum volume, but only tumour location influenced time to tumour regrowth. When considering treatment related factors, radiation dose was not significantly correlated with time to minimum volume or time to local regrowth, but it was correlated with probability for late normal tissue damage in the XRT alone group (p = 0.005). For the hyperthermia treatments, 13 of 15 tumour temperature distribution descriptors were correlated with time to minimum volume, but none were correlated with time to local regrowth. These results suggest that caution should be used in interpreting the value of temperature distribution descriptors in predicting for long-term local control after hyperthermia and radiotherapy, based on analysis of short-term responses.
引用
收藏
页码:309 / 320
页数:12
相关论文
共 50 条
  • [31] PHASE-II STUDY OF ELLIPTINIUM IN METASTATIC SOFT-TISSUE SARCOMA
    SOMERS, R
    ROUESSE, J
    VANOOSTEROM, A
    THOMAS, D
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (05): : 591 - 593
  • [32] Does a radiation dose-response relation exist concerning survival of patients who have soft-tissue sarcomas of the extremities? Radiation dose-response relation for soft-tissue sarcomas
    Wolfson, AH
    Benedetto, PW
    Mnaymneh, W
    Moffat, FL
    Robinson, DS
    Boyer, C
    Raub, WA
    Duncan, RC
    Markoe, AM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (03): : 270 - 274
  • [33] PHASE-II STUDY OF MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT - AN EORTC-SOFT-TISSUE-AND-BONE-SARCOMA-GROUP STUDY
    VERWEIJ, J
    KRZEMIENIECKI, K
    KOK, T
    POVEDA, A
    VANPOTTELSBERGHE, C
    VANGLABBEKE, M
    MOURIDSEN, H
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (02) : 208 - 209
  • [34] HIGH-DOSE DTIC IN ADVANCED SOFT-TISSUE SARCOMAS (STS) OF THE ADULT - A PHASE-II STUDY OF THE EORTC SOFT-TISSUE AND BONE SARCOMA GROUP
    BUESA, JM
    MOURIDSEN, H
    VANOOSTEROM, AT
    STEWARD, WT
    VERWEY, J
    THOMAS, D
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 73 - 73
  • [35] PHASE-II TRIAL OF PIROXANTRONE FOR ADVANCED OR METASTATIC SOFT-TISSUE SARCOMAS - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    ZALUPSKI, MM
    BENEDETTI, J
    BALCERZAK, SP
    HUTCHINS, LF
    BELT, RJ
    HANTEL, A
    GOODWIN, JW
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (04) : 337 - 341
  • [36] PHASE-II TRIAL OF DIANHYDROGALACTITOL IN ADVANCED SOFT-TISSUE AND BONY SARCOMAS - SOUTHWEST-ONCOLOGY-GROUP STUDY
    THIGPEN, JT
    SAMSON, MK
    CANCER TREATMENT REPORTS, 1979, 63 (04): : 553 - 555
  • [37] ACLACINOMYCIN-A (NSC-208734) - PHASE-II EVALUATION IN ADVANCED SOFT-TISSUE SARCOMAS
    OLENCKI, T
    PAZDUR, R
    SAMSON, M
    BAKER, L
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 185 - 185
  • [38] A PHASE-II TRIAL OF PACLITAXEL IN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMAS - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    BALCERZAK, SP
    BENEDETTI, J
    WEISS, GR
    NATALE, RB
    CANCER, 1995, 76 (11) : 2248 - 2252
  • [39] PHASE-II TRIAL OF METHYLENE DIMETHANE SULFONATE (MDMS) IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT
    STEWARD, WP
    MOURIDSEN, HT
    KERBRAT, P
    SOMERS, R
    VERWEIJ, J
    VANOOSTEROM, AT
    BLACKLEDGE, G
    HAVSTEEN, H
    THOMAS, D
    SYLVESTER, R
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (08): : 1251 - 1253
  • [40] PHASE-II EVALUATION OF GALLIUM NITRATE (NSC-15200) IN SOFT-TISSUE AND BONE SARCOMAS
    SAIKI, J
    STEPHENS, R
    FABIAN, C
    KRAUT, E
    FLETCHER, W
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 525 - 525